<sup>90</sup>Y/<sup>177</sup>Lu‐labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation
Rubel Chakravarty(Bhabha Atomic Research Centre), Ashutosh Dash(Bhabha Atomic Research Centre), K. V. Vimalnath Nair(Bhabha Atomic Research Centre), Haladhar Dev Sarma(Bhabha Atomic Research Centre), Sudipta Chakraborty, A. Rajeswari(Bhabha Atomic Research Centre)
Cited by 17
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99